Sotatercept-csrk

(Winrevair®)

Winrevair®

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (45 mg, 60 mg lyophilized cake or powder in a single-dose vial)
Drug ClassActivin signaling inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events.

Product Monograph / Prescribing Information

Document TitleYearSource
Winrevair (sotatercept-dsrk) Prescribing Information2024Merck & Co., Rahway, New Jersey

Systematic Reviews / Meta-Analyses